Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
AST.WS was delisted on the 26th of September, 2017.
36 hedge funds and large institutions have $406K invested in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
3% more capital invested
Capital invested by funds: $394K → $406K (+$12.4K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 37 → 36 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$369 |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$11 |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$7 |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.64K |
| 2 |
Morgan Stanley
New York
|
-$2.32K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$310 |
AST.WS Hedge Fund Activity: Q4 2016 in Review
36 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) for Q4 2016, worth a combined $406K — up 3.1% from $394K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of AST.WS and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was UBS Group, adding an estimated $369. The largest seller was Fidelity Investments, cutting an estimated $7.64K.
- 36 institutional investors held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) as of Q4 2016, down from 37 in Q3 2016.
- Funds reported $406K of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) stock for Q4 2016, up 3.1% quarter-over-quarter.
- 0 funds opened new Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) positions in Q4 2016 and 1 closed out, a net change of -1 holder.
- The largest Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) buyer in Q4 2016 was UBS Group, an estimated $369 added.
- The largest Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) seller in Q4 2016 was Fidelity Investments, an estimated $7.64K sold.
Based on aggregated 13F filings for Q4 2016.